• LinkedIn - Grey Circle
  • Facebook - Grey Circle
  • Instagram - Grey Circle

Updated: Aug 22, 2018

As clinical evidence relating to Hypochlorous acid technology continues to emerge as the superior base for advanced tissue therapies so does the scope of application. Leading this growth in clinical application, Te Arai BioFarma recently launched a new Microdacyn + Silicone gel combination product for scar management called Epicyn.

Epicyn is already supported by a recent double-blinded, randomised control trial whereby its efficacy in resolving common scar metrics such as; pliability, height, itch and pain was compared head to head with the current gold standard of topical scar therapy, 100% pure silicone gel (Kelo-Cote). (Gold et al 2017)

The synergistic effects of Microdaycn's HOCl in combination with silicone gel proved to be more effective than standard 100% silicone alone marking the next era in topical silicone scar management regimes, especially post wound healing with non-cytotoxic Microdacyn

Epicyn has a new healthcare professional brochure out now (seen here),

Continue the movement towards hypochlorous acid technology with Epicyn!

More product and clinical information on Epicyn can be found at www.epicyn.com.au or by calling Te Arai BioFarma on 1800 83 2724.

The World Health Organisation (WHO) Essential Medicines List (EML) committee considers Microdacyn technology during April 2017. Microdacyn is a super oxidised solution used to prevent and manage infection while clinically provides faster wound healing. The  Essential Medicines List contains carefully selected medicines and medical devices to meet the needs of near 84% of the worlds population, those living in poor, lower or middle income countries.

The EML is also a guide for the funded availability of medicines and medical devices through governments and organisations such as UNICEF.

A successful listing would mean the poor, lower and middle countries would be able to access the same wound care and infection control product Microdacyn, which is currently used in Australia, Europe, New Zealand and the USA.

The WHO is making a significant effort in sourcing non antibiotic technologies to combat the rising issue of drug resistance. WHO 2050 forecasts predict that drug resistance will be the leading case of death worldwide, greater than both cancer and cardiovascular disease.

Full details of the Microdacyn application are available to view here. Currently there is a substantial gap between countries in regard to wound care, for example the International Wound Infection Institute (IWII) 2016 guidelines note hydrogen peroxide products are not recommended, except in low income countries if no other products are available.

With the World Health Organisation (WHO) accepting a Microdacyn application lower income countries will be able to access the same products as the rest of world.

Background on the EML is here http://www.who.int/medicines/services/essmedicines_def/en/

For any queries please contact regulatory@tearaibiofarma.com

Microdacyn wound care solution has been included in the new International Wound Infection Institute (IWII) clinical practice Guidelines.

The IWII is a multidisciplinary international group of experts dedicated to sharing the latest developments in wound infection and infection prevention. The guidelines have a focus on #biofilm and wound infection.

Microdacyn is newly included as the only wound cleansing agent to rapidly penetrate and kill biofilm from within. The ability to penetrate and kill biofilm is significant given the growing understanding of biofilm as a major driver of non-healing wounds. 

Highlighting that older and common wound cleansing agents have demonstrated limited or no effect in reducing bacterial or fungal biofilm. In addition to chronic wounds the use of Microdacyn is recommended to prevent wound infection in higher risk people including:

  • The elderly

  • People with diabetes, immune disorders or Cardiovascular disease

and in higher risk wounds:

  • Dirty/contaminated wounds

  • Trauma with delayed treatment

  • Appropriate hair removal not possible

Despite previous use in Australia and New Zealand products containing hydrogen peroxide are no longer recommended for use. Hydrogen peroxide antiseptic products have a high risk of tissue damage and should only be used where no other product is available.

For the full Guidelines please visit here.

Microdacyn is available for all health care facility use please contact us for your local wholesaler or further information.